8-K
filed May 7, 2026, 7:59 PM ET
ticker AMPH
CIK 0001297184
earnings
confidence high
sentiment negative
materiality 0.75
Amphastar Q1 2026 GAAP net income drops 75% to $6.4M; adjusted EPS falls to $0.42
Amphastar Pharmaceuticals, Inc.
2026-Q1 EPS reported
$0.14
revenue$171,171,000
- Net revenues flat at $171.2M vs $170.5M YoY.
- GAAP net income $6.4M ($0.14 diluted EPS) vs $25.3M ($0.51) in Q1 2025.
- Adjusted non-GAAP net income $19.5M ($0.42 diluted EPS) vs $36.9M ($0.74).
- Launched Ipratropium Bromide HFA; signed license for synthetic corticotropin compound.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Amphastar Pharmaceuticals, Inc. reported three months ended March 31, 2026 results: net income Adjusted non-GAAP net income of $19.5 million, EPS $0.42 per share.
- Period
- three months ended March 31, 2026
- Net income
- Adjusted non-GAAP net income of $19.5 million
- EPS
- $0.42 per share
- Result
- reported results
Exact text from the filing
of $171.2 million for the three months ended March 31, 2026 - GAAP net income of $6.4 million, or $0.14 per share, for the first quarter - Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter - Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA – May 7, 2026 – Amphastar Pharmaceuticals,
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Amphastar Pharmaceuticals, Inc. reported three months ended March 31, 2026 results: net income Adjusted non-GAAP net income of $19.5 million, EPS $0.42 per share.
- Period
- three months ended March 31, 2026
- Net income
- Adjusted non-GAAP net income of $19.5 million
- EPS
- $0.42 per share
- Result
- reported results
Exact text from the filing
Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.